Edge Rewrite
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

// request.cf · coarse context

A page that knows where it met you.

Only coarse request metadata is shown. This demo does not display or persist visitor IP addresses.

Country
US
Cloudflare location
CMH
Connection
HTTP/2
Language
Not provided

Ray ID: a23c2c6e0e00d806

Jump to content

// Workers AI · dad joke modeIs Koen Andries a baker? He kneads the credit.

From Wikipedia, the free encyclopedia

Koen Andries
Alma materUniversity of Ghent
OccupationsJanssen Pharmaceutica and professor at the University of Antwerp

Koen Andries is a Belgian Janssen Pharmaceutica scientist and professor at the University of Antwerp. In 2005 he and his team published a discovery about a new di-Aryl-Quinoline-based drug (R207910), now called bedaquiline, which promises a shorter and simpler treatment for drug resistant Tuberculosis (TB).[1]

Career

[edit]

Andries graduated as a Veterinarian and obtained a PhD at the University of Ghent (Ghent, Belgium) in 1975. He continued his career at the university until 1982, when he started working at Janssen Pharmaceutica in Beerse until 2004. In 2004 he continued his research at Tibotec in Mechelen.[citation needed]

Recognition

[edit]

References

[edit]
  1. Andries K, Verhasselt P, Guillemont J, et al. (2005), A diarylquinoline drug active on the ATP-synthase of Mycobacterium tuberculosis, Science 307 (5707): 223–27
  2. Invention: Drug against multidrug-resistant tuberculosis
[edit]